Somatostatin Receptor Scintigraphy of Carcinoid Tumours Using the [111In-Dtpa-D-Phe1]-Octreotide
- 1 January 1993
- journal article
- research article
- Published by Taylor & Francis in Acta Oncologica
- Vol. 32 (7-8) , 783-786
- https://doi.org/10.3109/02841869309096136
Abstract
Somatostatin-receptor scintigraphy using the 111In-labelled somatostatin-analogue octreotide ([111In-DTPA-D-Phe1]-octreotide) was performed in 40 patients with carcinoid tumours. In 31/40 patients, this scintigraphy proved positive compared with the 33/40 patients whose tumours were disclosed on CT scans. In addition, 18 previously unidentified lesions were detected with this scintigraphy. Two of these lesions represented previously undetectable primary tumours. It is concluded that somatostatin receptor scintigraphy using [111In-DTPA-D-Phe1]-octreotide has a future role in the staging of patients with carcinoid disease.Keywords
This publication has 9 references indexed in Scilit:
- Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 1993
- Octreotide and interferon alfa: A new combination for the treatment of malignant carcinoid tumoursEuropean Journal Of Cancer, 1992
- The Role of Somatostatin and Its Analogs in the Diagnosis and Treatment of TumorsEndocrine Reviews, 1991
- Somatostatin-Receptor Imaging in the Localization of Endocrine TumorsNew England Journal of Medicine, 1990
- LOCALISATION OF ENDOCRINE-RELATED TUMOURS WITH RADIOIODINATED ANALOGUE OF SOMATOSTATINThe Lancet, 1989
- Treatment of the Malignant Carcinoid SyndromeNew England Journal of Medicine, 1986
- SomatostatinNew England Journal of Medicine, 1983
- EFFICACY OF SOMATOSTATIN IN A PATIENT WITH CARCINOID SYNDROMEThe Lancet, 1978
- Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth HormoneScience, 1973